Tag Archive for: haemodialysis

Invizius receives MHRA approval to commence First-in-Human clinical study of H-Guard® Priming Solution

Invizius Limited (“Invizius”), a biotechnology company developing second generation therapies for a range of complement-driven autoimmune and inflammatory disorders, is pleased to announce that it has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence its First-in-Human clinical study of lead product, H-Guard. The study will be conducted at the […]

Invizius announces ‘Angry Blood’ Haemodialysis Study and recruits its 300th patient

Novel study is investigating dysregulation of the complement system during standard hemodialysis therapy in relation to patient health outcomes Glasgow, Scotland, 13 June 2023 – Invizius Limited (“Invizius”), a biotechnology company developing second generation therapies for a range of complement-driven autoimmune and inflammatory disorders, is pleased to announce that it has recruited its 300th patient […]

Invizius Awarded Second Biomedical Catalyst Grant to Research Peritoneal Dialysis Indication for its H-Guard® Technology

Invizius Limited (“Invizius”), a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, today announces that it has been awarded a second Biomedical Catalyst grant (Feasibility & Primer Award) by Innovate UK to research a new field of application for its H-Guard® technology. Read more…

Invizius Awarded Major Biomedical Catalyst Grant to bring Anti-Inflammatory Haemodialysis Treatment to The Clinic

BioCity, Scotland, 30th March 2022  £1 million grant will support first-in-human clinical trials of H-Guard Invizius Limited (“Invizius”), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has been awarded a £1 million grant to bring H-Guard, its proprietary priming solution, designed to reduce the life-threatening inflammatory effects of […]